Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27986 | 0.89 | SRC (0.61) | KMT2AMEN1CYP1A2SRCALOX5 | |
| SCHEMBL29389002 | 0.89 | ALOX5 (0.52) | KMT2AMEN1CYP1A2ALOX5EPHX1 | |
| SCHEMBL29142063 | 0.81 | CYP1A2 (0.57) | KMT2AMEN1CYP1A2SRCALOX5 | |
| SCHEMBL8126795 | 0.80 | SRC (0.50) | KMT2ASRC | |
| SCHEMBL1581315 | 0.79 | SRC (0.76) | CYP1A2SRCALOX5EPHX1SMN1; SMN2 | |
| SCHEMBL11212242 | 0.78 | LMNA (0.50) | SRCALOX5CNR1SMN1; SMN2CES2 | |
| SCHEMBL351424 | 0.78 | CYP2C9 (0.49) | KMT2AMEN1CYP1A2SRCCYP2C19 | |
| SCHEMBL351263 | 0.78 | SRC (0.48) | SRCEPHX1CES2CES1 | |
| SCHEMBL11217394 | 0.78 | SRC (0.48) | SRCEPHX1SMN1; SMN2 | |
| SCHEMBL1657158 | 0.77 | SRC (0.58) | CYP1A2SRCCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015976-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANK TER HAFTUNG (DE) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015976-A1 | AUTOTAXIN INHIBITORS | ENPP2, PLA2G12A, LPCAT1 | KMT2A 1523/4885MEN1 186/4885CYP1A2 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.